- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03142516
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)
A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status
To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy.
The clinical hypothesis of this study is that the combination of panitumumab and FOLFIRI is a good treatment option in elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC. Another purpose of this clinical trial is to determine the RAS/BRAF mutation status in liquid biopsies at baseline and at the time of disease progression.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase II, multicentre, single-arm trial. Elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC will be evaluated before being included in this trial. Eligible patients will receive panitumumab plus FOLFIRI for disease control until disease progression, unacceptable toxicity, investigator decision or the patient's withdrawal of consent.
Tumour response will be evaluated by investigators using RECIST criteria (Response Evaluation Criteria in Solid Tumours) version 1.1. Tumour response will be evaluated every 8 weeks until disease progression is documented. Disease response will be confirmed no less than 28 days after the criteria for response are first met. Radiographic progression of subjects with symptoms indicating disease progression will be evaluated at the time of symptom onset.
Following disease progression, information will be collected on the subsequent lines of treatment chosen by the investigator and survival at follow-up visits held every 12 weeks (± 4 weeks) until completion of the trial (approximately 24 months after inclusion of the last patient in the trial).
A blood sample will be taken at baseline and at the time of disease progression in order to determine the RAS/BRAF mutation status.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic
-
Elda, Spain, 03600
- Hospital General Universitario de Elda
-
Lleida, Spain, 25198
- Hospital Universitario Arnau de Vilanova
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Murcia, Spain, 30008
- Hospital General Universitario Morales Meseguer
-
Palma, Spain, 07020
- Hospital Universitario Son Espases
-
Sabadell, Spain, 08208
- Hospital Parc Tauli
-
Zaragoza, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
- ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals
-
Sant Joan Despí, Barcelona, Spain, 08970
- Hospital Sant Joan Despí-Moisés Broggi
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro-Majadahonda
-
Móstoles, Madrid, Spain, 28933
- Hospital Universitario Rey Juan Carlos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females ≥ 70 years,
- Able to understand, sign and date an informed consent form approved by the IEC,
- Histologically confirmed colorectal carcinoma with metastatic disease,
- RAS/BRAF wild-type status in solid biopsy confirmed prior to inclusion of the study,
- No previous treatment for metastatic disease,
- Patients starting therapy with FOLFIRI + panitumumab with a treatment aim other than achieving potential resectability of the disease,
- Independence in activities of daily living (ADL) based on the Katz Index and in instrumental activities of daily living (IAL) based on the Lawton Index,
- Having no or only one comorbidity according to the Charlson Comorbidity Index. The following ones are not considered comorbidities as long as it is provided they are adequately controlled with medication: gastroduodenal ulcer, diabetes without target organs' damage, chronic respiratory disease and connective tissue disease.
- Presence of at least one unidimensional measurable lesion ≥ 10 mm according to RECIST criteria (version 1.1),
- ECOG (Eastern Cooperative Oncology Group) performance status of 0-1,
- Adequate bone marrow function: neutrophils ≥ 1.5 x 10^9/l; platelets ≥ 100 x 10^9/l; haemoglobin ≥ 9 g/dl,
Hepatic, renal and metabolic function as follows:
- Total bilirubin count ≤ 1.5 x ULN; ALT and AST < 5 x ULN;
- Renal function, calculated creatinine clearance or 24-hour creatinine clearance ≥ 50 ml/min;
- Magnesium > LLN
Exclusion Criteria:
- Diagnosed or suspected central nervous system (CNS) metastasis,
- Patients with initially resectable metastases at the time of diagnosis of metastatic disease.
- History or presence of another malignancy, with the exception of curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer or any curatively treated solid tumour, with no active disease or administration of treatment within 5 years prior to inclusion in the study,
- Prior treatment with irinotecan,
- Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before metastatic disease was diagnosed,
- Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, cetuximab), anti- vascular endothelial growth factor (VEGF) or treatment with small molecule EGFR inhibitors (eg, erlotinib),
- Unresolved toxicities from prior systemic treatment that, in the investigator's opinion, make the patient unsuitable for inclusion,
- Hormone therapy, immunotherapy with experimental or approved antibodies/proteins (e.g. bevacizumab) ≤ 30 days prior to inclusion,
- Evidence of previous acute hypersensitivity reaction of any grade to any of the components of the treatment,
- History of interstitial lung disease or pulmonary fibrosis or signs of interstitial lung disease or pulmonary fibrosis on baseline CT,
- Presence of geriatric syndromes, defined as dementia, repeated falls, fecal incontinence or urinary incontinence,
- Acute or subacute bowel obstruction and/or active bowel disease or another bowel disease causing chronic diarrhoea (defined as diarrhoea of grade ≥ 2 according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE version 4.03),
- Significant cardiovascular disease, including unstable angina pectoris or myocardial infarction within 12 months prior to inclusion in the study,
- History of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency,
- Positive test result for human immunodeficiency virus, hepatitis C virus, chronic active hepatitis B infection,
- Treatment for systemic infection within 14 days prior to the start of the study treatment,
- Clinically significant sensory peripheral neuropathy,
- Any concurrent disease that may increase the risk associated with study participation or may interfere with the interpretation of study results,
- Any investigational product within 30 days prior to inclusion,
- Surgery (not including diagnostic biopsy or the placement of a central line) and/or radiotherapy within 28 days prior to inclusion in the study,
- Males whose partner is of child-bearing age and who does not agree to use adequate contraceptive precautions, i.e. double-barrier methods (e.g. diaphragm plus condom) or abstinence for the duration of the study and for 1 month after the last administration of the study drug,
- Subjects who do not agree or are unable to meet the study requirements,
- Psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and the follow-up schedule. Such conditions should be discussed with the patient before enrolment in the clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: FOLFIRI + panitumumab
All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
|
Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Other Names:
Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Other Names:
5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Other Names:
Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle.
If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival at one year
Time Frame: 12 months after inclusion
|
Percentage of subjects still alive and progression free 12 months after inclusion in the study
|
12 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 42 months
|
Time (months) from inclusion in the trial until disease progression or death
|
42 months
|
Objective response rate
Time Frame: 42 months
|
Proportion of patients with an objective response (complete or partial response) according to RECIST 1.1 criteria
|
42 months
|
Disease control rate
Time Frame: 42 months
|
Proportion of patients with disease control (complete response, partial response or stable disease)
|
42 months
|
Duration of response
Time Frame: 42 months
|
Time (months) from the first confirmation of objective response according to RECIST 1.1 criteria until disease progression or death
|
42 months
|
Time to response
Time Frame: 18 months
|
Time (months) from inclusion in the trial until the date of the first confirmation of objective response according to RECIST 1.1 criteria
|
18 months
|
Overall survival (OS)
Time Frame: 42 months
|
Time (months) from inclusion in the trial until death of the patient
|
42 months
|
Time to treatment failure
Time Frame: 18 months
|
Time (months) from inclusion in the trial until progression, death or discontinuation due to toxicity
|
18 months
|
Proportion of patients with early tumour shrinkage (ETS)
Time Frame: 2 months
|
Defined as tumour shrinkage ≥ 30% at the first tumour assessment based on RECIST 1.1 criteria
|
2 months
|
Depth of response (DpR)
Time Frame: 18 months
|
Measured as the maximum reduction ratio (percentage) of the tumour compared with baseline measurement (sum of diameters of the lesions) at the different assessments based on RECIST 1.1 criteria
|
18 months
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 42 months
|
Incidence and severity of adverse events.
AEs description according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
|
42 months
|
Combined analysis of prognostic factors in metastatic disease
Time Frame: 42 months
|
To analyse the number of lesions in liver and lung disease (1-3 vs 4-9 or ≥10), and the size of the largest lesion (<5 cm or ≥ 5 cm), in correlation with the analytical values, mainly LDH and AP values.
|
42 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RAS/BRAF conversion proportion
Time Frame: At treatment initiation and at the time of PD (42 months)
|
Conversion rate of RAS/BRAF status at first-line treatment initiation and at the time of disease progression
|
At treatment initiation and at the time of PD (42 months)
|
RAS/BRAF mutations' detection proportion
Time Frame: At baseline
|
Detection rate of RAS/BRAF mutations in liquid biopsies at baseline in subjects with RAS/BRAF wild-type mCRC according to the solid biopsy analysis
|
At baseline
|
Collaborators and Investigators
Investigators
- Study Director: Jaime Feliu, MD, Hospital Universitario La Paz
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Neoplasms
- Colorectal Neoplasms
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Hematinics
- Fluorouracil
- Leucovorin
- Irinotecan
- Levoleucovorin
- Folic Acid
- Panitumumab
Other Study ID Numbers
- GEMCAD-16-03
- 2017-001639-38 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Metastasis
-
Betta Pharmaceuticals Co., Ltd.Recruiting
-
BayerCompleted
-
BayerCompletedNeoplasm Metastasis / Bone and BonesBelgium, Spain, Taiwan, United States, Japan, Russian Federation, Canada, Finland, Korea, Republic of, Singapore, Australia, Germany, Israel, United Kingdom, Italy, France, Poland, Brazil, Czechia, Norway, Sweden, Hong Kong
-
National Cancer Institute (NCI)TerminatedCancer | Neoplasm Metastasis | Metastasis | Neoplasm | Radiation OncologyUnited States
-
MedtronicNeuroCompletedMetastasis Spine | Metastasis to BoneUnited States, Luxembourg, Germany, France, Canada
-
Cho Ray HospitalUniversity of Medicine and Pharmacy at Ho Chi Minh CityRecruitingSynchronous Neoplasm | Liver Metastasis Colon CancerVietnam
-
Li MinRecruiting
-
Da FuGanzhou City People's HospitalRecruiting
-
University of Mississippi Medical CenterCompletedMetastasisUnited States
-
The Netherlands Cancer InstituteCompletedLymph Node Metastasis | Image-guide SurgeryNetherlands
Clinical Trials on Panitumumab
-
University of Alabama at BirminghamRecruiting
-
Spanish Cooperative Group for the Treatment of...AmgenCompleted
-
Radboud University Medical CenterTerminatedIrresectable Squamous Cell or Adenocarcinoma of the OesophagusNetherlands
-
TakedaCompleted
-
WiSP Wissenschaftlicher Service Pharma GmbHGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHTerminatedUrinary Bladder CancerGermany
-
Cliniques universitaires Saint-Luc- Université...Terminated
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colo-rectal CancerItaly
-
Hellenic Cooperative Oncology GroupCompleted
-
University of UtahTerminatedKRAS and NRAS Wild-type Colorectal CancerUnited States
-
Matteo's FriendsRecruitingRecurrence Free SurvivalItaly